Patient-reported quality of life refers to the physical, functional, and psychosocial consequences of disease and treatment as experienced by patients themselves. There is emerging evidence for a genetic basis of patient-reported quality of life.
The overall objective of the GeneQol Consortium is to establish strong collaborative and interdisciplinary relationships to conduct clinically relevant research to identify and investigate biological mechanisms, potential genes and genetic variants involved in quality of life.
The GeneQol Consortium aims to facilitate such investigations by supporting communication among members and with others outside the Consortium, and thus enabling networking and access to knowledge, skills, and ideas. The overall aim is to compile and pool existing and new data to carry out genetic analyses. The Consortium targets data of patients as well as general populations.
Our vision for the future is that emerging insight into the genetic basis of patient-reported quality-of-life outcomes will ultimately allow us to explore new pathways for improving patient care. If we can identify patients who are susceptible to poor quality of life, we will be able to better tailor preventive strategies and/or specific support and treatment.
The GeneQol Consortium currently involves more than 40 members representing a wide range of disciplines, including cellular biology, molecular biology, behavioral genetics, pharmacogenetics, biological psychology, genetic epidemiology, statistical genetics, sociology, psychiatry, medical psychology, clinical psychology, nursing, and oncology.
The members live in 11 different countries, indicated in green.